Psych CASC / OSCE · Psychopharmacology — metabolic syndrome and psychotropic monitoring
Explaining antipsychotic weight gain and a monitoring plan (CASC)
CASC-style station: explain metabolic risk in plain language, validate anger, negotiate monitoring and change options (lifestyle, switch, metformin) without abandoning relapse prevention.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes with the parents (and young person if present). Validate concern about weight and glucose, explain that some antipsychotics — including olanzapine — carry higher metabolic risk especially in young people, outline what monitoring should look like, and negotiate a plan: lifestyle support, possible switch to a lower-metabolic agent, possible metformin, and why abrupt stop of all treatment risks relapse. Avoid jargon without explanation. Do not promise zero risk. Do not dismiss their anger.[1][2][6]
Marking domains
Empathy and agenda setting; accurate plain-language metabolic explanation; youth risk awareness; structured monitoring plan; collaborative options (switch/metformin/lifestyle); relapse-risk balance; shared decision and written follow-up; avoids both minimisation and “stop everything” panic.[1][2][3]
Model communication map
- Open: thank them for raising this; name shared goals — keep him well for school and protect long-term physical health.[1]
- Validate: weight and glucose changes are real, expected more with some medicines, and more concerning in adolescents; you should have been tracking this early.[2][6]
- Plain mechanism: some medicines increase hunger and change how the body handles sugar and fat — not a moral failure of the family.[6]
- Why medicine helped: reduced psychosis symptoms; sudden full stop risks return of illness that also harms life expectancy and safety.[1]
- Options now: (a) structured lifestyle support; (b) switch to a medicine with lower average weight effect if symptoms allow; (c) discuss metformin as an add-on studied for antipsychotic weight problems; (d) treat abnormal glucose with medical colleagues.[3][4][5]
- Monitoring promise: weight/waist/BP and labs on a clear timetable (early weeks then regular reviews) with named responsibility (clinic vs GP).[1]
- Safety-net: thirst, lots of urine, vomiting, confusion → urgent care for possible dangerous high sugar.[1]
- Close: summarise plan, written leaflet, follow-up date, invite questions.[1]
Common fails
- “All antipsychotics are the same for weight.”[6]
- Agreeing to stop all medicine today with no relapse plan.[1]
- Blaming parents’ cooking as the sole cause.[2]
- Offering metformin without mentioning monitoring, side effects, or that lifestyle still matters.[3][4]
- Using only acronyms (MetS, SGA, HbA1c) without checking understanding.[1]
References
- [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
- [2]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
- [3]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
- [4]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
- [5]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
- [6]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730